NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Saquib Ahmad: Management of DVT and Follow-Up
Dr Saquib Ahmad/LinkedIn
Nov 27, 2025, 05:05

Saquib Ahmad: Management of DVT and Follow-Up

Saquib Ahmad, General Practitioner at Khyber Medical Centre Madinat Zyed, posted on LinkedIn:

”Management of DVT and Follow-Up

1. Initial Anticoagulation (First 3 Months)

All patients with acute DVT require therapeutic anticoagulation for a minimum of three months.

2. Treatment Duration After the First 3 Months

The decision to continue, reduce, or stop anticoagulation depends on whether the DVT was provoked, unprovoked, or associated with a persistent risk factor. This step is the key determinant of long-term outcomes.

3. Anticoagulant Options for All Acute DVT

The following medications may be used for initial treatment.

  • Apixaban: 10 mg twice daily for 7 days, followed by 5 mg twice daily
  • Rivaroxaban: 15 mg twice daily for 21 days, followed by 20 mg once daily
  • Dabigatran: 150 mg twice daily
  • Edoxaban: 60 mg once daily (started after 5 days of heparin)
  • Warfarin: use only if DOAC is unsuitable

Duration: Minimum treatment duration is 3 months for all cases of DVT.

Decide Duration After 3 Months (Most Important Step)

A. Provoked DVT (temporary risk factor)

Examples: surgery, trauma, immobilization, long flight, OCPs.
• Duration: 3 months only
• No need to extend therapy
• Do NOT check D-dimer for stopping decision

Recurrence risk: very low (1–3%/year)

B. Unprovoked DVT (no clear trigger)
• Duration: Extended therapy recommended
• Either full dose or reduced-dose DOAC
• Recurrence risk high (10% in 1st year)

D-dimer use:
Check D-dimer 4-6 weeks after stopping anticoagulation
• If high → restart DOAC long term
• If normal → optional observation

C. DVT with persistent risk factor (cancer, thrombophilia, chronic disease)
• Duration: Indefinite (lifelong) anticoagulation
• D-dimer not reliable → don’t use for decisions

DOAC Dosing for Long-Term Recurrence Prevention

(AKA “secondary prevention” or “extended therapy”)

After the first 3–6 months, reduce to secondary-prevention dose:
• Apixaban 2.5 mg BID
• Rivaroxaban 10 mg daily

These doses lower recurrence by 80–90% with minimal bleeding risk.

When to Repeat D-Dimer (Very Important)

Use ONLY in unprovoked DVT when deciding whether to stop anticoagulation.

When to measure:

  • 4–6 weeks after fully stopping DOAC/warfarin
  • Patient should be clinically stable
  • No acute illness, no post-op period (false elevation)

How to interpret:
• Normal D-dimer: Indicates low recurrence risk and it is acceptable to remain off anticoagulation, with close follow-up.
• Elevated D-dimer: Indicates high recurrence risk and anticoagulation should be restarted or continued indefinitely using a DOAC.

DO NOT repeat D-dimer:

  • In provoked DVT
  • In cancer
  • While patient is still on anticoagulation
  • During pregnancy or postpartum
  • After surgery or infection (false positives)
  • Courtesy MRCP UK”

 

Stay updated with Hemostasis Today.

 

Anticoagulation deep vein thrombosis DVT DVT Follow-Up DVT Prevention Health Hematology Hemostasis Hemostasis Today Khyber Medical Centre Madinat Zyed Medicine Saquib Ahmad thrombosis
NewsFeed